• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Photodiagnosis and Photodynamic Therapy >Prognostic factors for combined ranibizumab and prompt verteporfin photodynamic therapy for polypoidal choroidal vasculopathy
【24h】

Prognostic factors for combined ranibizumab and prompt verteporfin photodynamic therapy for polypoidal choroidal vasculopathy

机译：雷珠单抗联合维替泊芬即时光动力疗法治疗息肉样脉络膜脉络膜血管病的预后因素

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: To investigate the prognostic factors for the combined therapy of ranibizumab and prompt verteporfin photodynamic therapy (vPDT) for eyes with polypoidal choroidal vasculopathy (PCV).Methods: Sixty-two PCV eyes of 62 patients that received the initial treatment of intravitreal ranibizumab followed by vPDT within 1 week plus a 2nd intravitreal ranibizumab 1 month later in one single medical center were retrospectively enrolled. Best-corrected visual acuity (BCVA) and parameters obtained from optical coherence tomography at baseline, 3 months, 6 months and 1 year were measured and compared. Factors associated with polyp regression, recurrent hemorrhage and visual improvement were analyzed.Results: After the loading treatment, complete and partial polyp regression was achieved in 53.6% and 39.3% of cases, respectively at Month 3. The mean logarithm of the minimum angle of resolution of BCVA improved from 0.64 +/- 0.38 to 0.55 +/- 0.46 (P = 0.008) at Month 12. Recurrent hemorrhage (P = 0.001) and previous antivascular endothelial growth factor (VEGF) treatment (P = 0.017) were associated with poorer visual improvement at Month 12. Incomplete polyp regression (P = 0.038) and previous anti-VEGF treatment (P = 0.005) were associated with a higher risk of recurrent hemorrhage.Conclusions: Recurrent hemorrhage was associated with poor visual improvement after combined ranibizumab and vPDT for PCV. Complete polyp eradication was associated with a lower risk of recurrent hemorrhage. Patients who had previously received anti-VEGF were associated with recurrent hemorrhage and poor visual improvement; more frequent follow-ups and more aggressive subsequent treatments may be needed for these cases.
机译：目的：探讨兰尼单抗联合速效维替泊芬光动力疗法（vPDT）合并息肉样脉络膜血管病（PCV）的预后因素。方法：62例接受玻璃体腔内雷珠单抗初始治疗的62例PCV眼于1周内通过vPDT进行回顾性研究，并于1个月后在一个单一的医疗中心接受第二次玻璃体内兰尼单抗治疗。测量并比较最佳校正视力（BCVA）和从基线，3个月，6个月和1年的光学相干断层扫描获得的参数。结果：在接受负荷治疗后，在第3个月，分别有53.6％和39.3％的病例实现了完全和部分息肉消退，平均息肉最小角度的对数。第12个月时BCVA的分辨率从0.64 +/- 0.38提高到0.55 +/- 0.46（P = 0.008），复发性出血（P = 0.001）和先前的抗血管内皮生长因子（VEGF）治疗（P = 0.017）与在第12个月时视力改善较差。息肉消退不完全（P = 0.038）和先前的抗VEGF治疗（P = 0.005）与复发性出血的风险较高相关。用于PCV的vPDT。彻底根除息肉与再次出血的风险较低有关。先前曾接受抗VEGF的患者伴有复发性出血和视力改善不佳。这些情况可能需要更频繁的随访和更积极的后续治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号